Form 4: Zivo Bioscience Director Acquires Shares in Exchange for Obligation Release

Laith L. Yaldoo, a director and 10% owner of Zivo Bioscience, Inc., acquired shares in exchange for the release of certain company obligations.

Summary

• On January 22, 2025, Laith L. Yaldoo, a director and 10% owner of Zivo Bioscience, Inc. (ZIVO), acquired 7,200 shares of common stock at a price of $17.528 per share.
• Additionally, Yaldoo acquired 2,880 shares of common stock at the same price on the same date.
• These shares were acquired indirectly through HEP Investments LLC.
• The acquisitions were made in exchange for the release of certain obligations of Zivo Bioscience under the License Co-Development Participation Agreement.
• Following these transactions, Yaldoo beneficially owns 554,626 shares through HEP Investments LLC.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The transaction itself doesn't necessarily indicate positive or negative sentiment about the company's prospects.

Positives

• A director's increased stake in the company can be seen as a sign of confidence in the company's future.

Industry Context

This transaction is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder confidence due to the director's increased investment.

Key Dates

Keywords

Zivo Bioscience, Director, Share Acquisition, Form 4, Beneficial Ownership, Laith L. Yaldoo, HEP Investments LLC, License Co-Development Participation Agreement